Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
Pather S, Charpentier N, van den Ouweland F, Rizzi R, Finlayson A, Salisch N, Muik A, Lindemann C, Khanim R, Abduljawad S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). Pather S, et al. Among authors: chen rt. Vaccine. 2024 Sep 17;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Epub 2024 Aug 27. Vaccine. 2024. PMID: 39197299 Free article. Review.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Estephan L, Liu LT, Lien CE, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO ex-V3SWG). Estephan L, et al. Among authors: chen rt. Vaccine. 2023 Apr 6;41(15):2615-2629. doi: 10.1016/j.vaccine.2023.02.083. Epub 2023 Mar 3. Vaccine. 2023. PMID: 36925422 Free PMC article.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Wilkinson B, Patel KS, Smith K, Walker R, Wang C, Greene AM, Smith G, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO; (ex-V3SWG). Wilkinson B, et al. Among authors: chen rt. Vaccine. 2023 Oct 26;41(45):6762-6773. doi: 10.1016/j.vaccine.2023.07.040. Epub 2023 Sep 20. Vaccine. 2023. PMID: 37739888 Free article.
The Brighton collaboration standardized module for vaccine benefit-risk assessment.
Levitan B, Hadler SC, Hurst W, Izurieta HS, Smith ER, Baker NL, Bauchau V, Chandler R, Chen RT, Craig D, King J, Pitisuttithum P, Strauss W, Tomczyk S, Zafack J, Kochhar S. Levitan B, et al. Among authors: chen rt. Vaccine. 2024 Feb 6;42(4):972-986. doi: 10.1016/j.vaccine.2023.09.039. Epub 2023 Dec 21. Vaccine. 2024. PMID: 38135642 Free article.
Benefit-risk assessment of vaccines.
Kochhar S, Izurieta HS, Chandler RE, Hacker A, Chen RT, Levitan B. Kochhar S, et al. Among authors: chen rt. Vaccine. 2024 Feb 6;42(4):969-971. doi: 10.1016/j.vaccine.2023.07.041. Epub 2023 Aug 8. Vaccine. 2024. PMID: 37563049 Free article.
Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group.
Chandler RE, Balakrishnan MR, Brasseur D, Bryan P, Espie E, Hartmann K, Jouquelet-Royer C, Milligan J, Nesbitt L, Pal S, Precioso A, Takey P, Chen RT; COVAX Vaccine Safety Working Group. Chandler RE, et al. Among authors: chen rt. BMJ Glob Health. 2024 Mar 7;9(3):e014544. doi: 10.1136/bmjgh-2023-014544. BMJ Glob Health. 2024. PMID: 38453518 Free PMC article. Review.
Funding Postauthorization Vaccine-Safety Science.
Salmon DA, Orenstein WA, Plotkin SA, Chen RT. Salmon DA, et al. Among authors: chen rt. N Engl J Med. 2024 Jul 11;391(2):102-105. doi: 10.1056/NEJMp2402379. Epub 2024 Jul 6. N Engl J Med. 2024. PMID: 38973739 No abstract available.
360 results